Compare · MOS vs NITO
MOS vs NITO
Side-by-side comparison of Mosaic Company (MOS) and N2OFF Inc. (NITO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOS and NITO operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- MOS carries a market cap of $7.41B.
- MOS has hit the wire 16 times in the past 4 weeks while NITO has been quiet.
- MOS has more recent analyst coverage (25 ratings vs 0 for NITO).
- Company
- Mosaic Company
- N2OFF Inc.
- Price
- -
- -
- Market cap
- $7.41B
- -
- 1M return
- +1.39%
- -
- 1Y return
- -36.72%
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 0
Mosaic Company
The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients in North America and internationally. The company operates through three segments: Phosphates, Potash, and Mosaic Fertilizantes. It owns and operates mines, which produce concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products; and phosphate-based animal feed ingredients primarily under the Biofos and Nexfos brand names, as well as produces a double sulfate of potash magnesia product under K-Mag brand name. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant. In addition, it provides nitrogen-based crop nutrients and animal feed ingredients, and other ancillary services; and purchases and sells phosphates, potash, and nitrogen products. The company sells its products to wholesale distributors, retail chains, farmers, cooperatives, independent retailers, and national accounts. The Mosaic Company was incorporated in 2004 and is headquartered in Tampa, Florida.
Latest MOS
- Director Kuzenko Jody Lynne converted options into 4,873 shares, increasing direct ownership by 57% to 13,444 units (SEC Form 4)
- Director Gitzel Timothy S. converted options into 4,873 shares, increasing direct ownership by 7% to 79,527 units (SEC Form 4)
- Director Shanahan Kathleen M converted options into 4,873 shares, increasing direct ownership by 202% to 7,286 units (SEC Form 4)
- Director Watkins Gretchen H converted options into 4,873 shares, increasing direct ownership by 16% to 35,934 units (SEC Form 4)
- Director Koenig Emery N. converted options into 4,873 shares, increasing direct ownership by 6% to 86,228 units (SEC Form 4)
- Director Teixeira Joao Roberto Goncalves converted options into 4,873 shares, increasing direct ownership by 57% to 13,442 units (SEC Form 4)
- Director Beebe Cheryl K converted options into 2,437 shares, increasing direct ownership by 6% to 46,691 units (SEC Form 4)
- Director Seaton David Thomas converted options into 3,167 shares, increasing direct ownership by 7% to 51,089 units (SEC Form 4)
- Director Ebel Gregory L converted options into 7,310 shares (SEC Form 4)
- Director Westbrook Kelvin R converted options into 2,437 shares, increasing direct ownership by 7% to 39,807 units (SEC Form 4)
Latest NITO
- SEC Form PRE 14A filed by N2OFF Inc.
- N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
- MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases
- Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)
- Chief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions